Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial-Reference-Cited by-同舟云学术

Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial

Published:2022-02 Issue:10324 Volume:399 Page:541-553
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Gershenson David M,Miller Austin,Brady William E,Paul James,Carty Karen,Rodgers William,Millan David,Coleman Robert L,Moore Kathleen N,Banerjee Susana,Connolly Kate,Secord Angeles Alvarez,O'Malley David M,Dorigo Oliver,Gaillard Stephanie,Gabra Hani,Slomovitz Brian,Hanjani Parviz,Farley John,Churchman Michael,Ewing Ailith,Hollis Robert L,Herrington C Simon,Huang Helen Q,Wenzel Lari,Gourley Charlie

Publisher

Elsevier BV

Subject

General Medicine

Reference31 articles.

1. WHO classification of tumours of the female reproductive organs: WHO classification of tumours;Kurman,2014

2. Ovarian carcinomas: at least five different diseases with distinct histological features and molecular genetics;Prat;Hum Pathol,2018

3. Genetic and molecular changes in ovarian cancer;Hollis;Cancer Biol Med,2016

4. Rethinking ovarian cancer: recommendations for improving outcomes;Vaughan;Nat Rev Cancer,2011

5. Reclassification of serous ovarian carcinoma by a 2-tier system: a Gynecologic Oncology Group Study;Bodurka;Cancer,2012

Cited by 73 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mesonephric and mesonephric-like adenocarcinomas of gynecologic origin: A single-center experience with molecular characterization, treatment, and oncologic outcomes;Gynecologic Oncology;2024-03

2. Complete Response With Trametinib in Advanced Low-Grade Serous Ovarian Carcinoma: A Case Report;Cureus;2024-02-05

3. ESGO–ESMO–ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease;Annals of Oncology;2024-02

4. Understanding Less Common Ovarian Cancers (LCOCs): Updated Review and Management Strategies;Indian Journal of Gynecologic Oncology;2024-01-19

5. Natural products targeting the MAPK-signaling pathway in cancer: overview;Journal of Cancer Research and Clinical Oncology;2024-01-09